Ascendis Pharma A/S

AI Score

0

Unlock

156.10
12.02 (8.34%)
At close: Feb 18, 2025, 3:59 PM
156.19
0.05%
After-hours: Feb 18, 2025, 04:00 PM EST
undefined%
Bid 146.38
Market Cap 9.34B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -6.79
PE Ratio (ttm) -22.99
Forward PE n/a
Analyst Buy
Ask 166
Volume 736,892
Avg. Volume (20D) 445,942
Open 145.50
Previous Close 144.08
Day's Range 145.00 - 157.10
52-Week Range 111.09 - 161.00
Beta undefined

About ASND

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops Tra...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 28, 2015
Employees 1,017
Stock Exchange NASDAQ
Ticker Symbol ASND
Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for ASND stock is "Buy." The 12-month stock price forecast is $186, which is an increase of 19.15% from the latest price.

Buy 92.86%
Hold 7.14%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Ascendis Pharma A/S is scheduled to release its earnings on May 1, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
+8.41%
Ascendis Pharma shares are trading higher after Ev... Unlock content with Pro Subscription
5 days ago
+12.96%
Ascendis Pharma shares are trading higher after the company reported better-than-expected Q4 financial results and authorized a share repurchase program worth $18.25 million.